TY - JOUR
T1 - Recommended and observed statin use among US adults with and without cancer
AU - Kobo, Ofer
AU - Michos, Erin D.
AU - Roguin, Ariel
AU - Bagur, Rodrigo
AU - Gulati, Martha
AU - Mamas, Mamas A.
N1 - Publisher Copyright:
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology. All rights reserved.
PY - 2024/8/1
Y1 - 2024/8/1
N2 - Aims Patients with cancer are at increased cardiovascular (CV) risk. We aimed to compare the recommended and observed statin use among individuals with and without cancer. Methods Using three 2-year cycles from the National Health and Nutrition Examination Survey (2013–18), we analysed data from and results 17 050 US adults. We compared the prevalence of Class 1 statin recommendations and use between individuals with and without cancer, overall, and among different demographic groups. Individuals with a history of cancer were older and had a higher burden of comorbidities. Stratified by age groups, they were more likely to have a secondary prevention indication compared with individuals without cancer but not a primary prevention indication for statin. Among individuals with an indication for statin therapy, the prevalence of statin use was higher in the cancer group compared with those without cancer (60.8% vs. 47.8%, P< 0.001), regardless of sex, type of indication (primary vs. secondary prevention), and education level. However, the higher prevalence of statin use in the cancer group was noted among younger individuals, ethnic minorities, and those with lower family income. Conclusion Our finding highlights the importance of optimization of CV health in patients with cancer, as individuals with cancer were more likely to have a Class 1 indication for statin treatment when compared with individuals without cancer. Important differences in statin use among cohorts based on sex, age, ethnicity, and socioeconomic status were identified, which may provide a framework through which CV risk factor control can be targeted in this population.
AB - Aims Patients with cancer are at increased cardiovascular (CV) risk. We aimed to compare the recommended and observed statin use among individuals with and without cancer. Methods Using three 2-year cycles from the National Health and Nutrition Examination Survey (2013–18), we analysed data from and results 17 050 US adults. We compared the prevalence of Class 1 statin recommendations and use between individuals with and without cancer, overall, and among different demographic groups. Individuals with a history of cancer were older and had a higher burden of comorbidities. Stratified by age groups, they were more likely to have a secondary prevention indication compared with individuals without cancer but not a primary prevention indication for statin. Among individuals with an indication for statin therapy, the prevalence of statin use was higher in the cancer group compared with those without cancer (60.8% vs. 47.8%, P< 0.001), regardless of sex, type of indication (primary vs. secondary prevention), and education level. However, the higher prevalence of statin use in the cancer group was noted among younger individuals, ethnic minorities, and those with lower family income. Conclusion Our finding highlights the importance of optimization of CV health in patients with cancer, as individuals with cancer were more likely to have a Class 1 indication for statin treatment when compared with individuals without cancer. Important differences in statin use among cohorts based on sex, age, ethnicity, and socioeconomic status were identified, which may provide a framework through which CV risk factor control can be targeted in this population.
KW - Cardio-oncology
KW - Prevention
KW - Statin
UR - http://www.scopus.com/inward/record.url?scp=85201029645&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85201029645&partnerID=8YFLogxK
U2 - 10.1093/eurjpc/zwae057
DO - 10.1093/eurjpc/zwae057
M3 - Article
C2 - 38332751
AN - SCOPUS:85201029645
SN - 2047-4873
VL - 31
SP - 1251
EP - 1257
JO - European Journal of Preventive Cardiology
JF - European Journal of Preventive Cardiology
IS - 10
ER -